Division of Product Quality and Research, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-002, USA.
Int J Pharm. 2012 Jan 17;422(1-2):91-100. doi: 10.1016/j.ijpharm.2011.10.033. Epub 2011 Oct 21.
The aim of this investigation was to evaluate the complexation potential of brompheniramine maleate (BPM) and tannic acid (TA) for sustained release and taste masking effects. The complexes (1:1-1:7 TA to BPM ratio) were prepared by the solvent evaporation method using methanol, phosphate buffer pH 6.8 or 0.1N HCl as common solvents. The complexes were characterized microscopically by scanning electron microscopy (SEM), chemically by Fourier transform infrared (FTIR) and solid-state NMR (SSNMR), thermally by differential scanning calorimetry (DSC), for crystallinity by powder X-ray powder diffraction (PXRD), for organoleptic evaluation by electronic tongue (e-tongue), and for solubility in 0.1N HCl and phosphate buffer pH 6.8. The dissolution studies were carried out using the USP II method at 50 rpm in 500 ml of dissolution media (0.1N HCl or phosphate buffer pH 6.8). SEM images revealed that the morphology of complexes were completely different from the individual components, and all complexes had the same morphological characteristics, irrespective of the solvent used for their preparation, pH or ratio of BPM and TA. The FTIR spectra showed the presence of chemical interactions between the TA and BPM. DSC, PXRD and SSNMR indicated that the drug lost its crystalline nature by formation of the complex. Complexation has significantly reduced the solubility of BPM and sustained the drug release up to 24h in phosphate buffer pH 6.8 media. The bitter taste of the BPM was completely masked which was indicated by Euclidean distance values which was far from the drug but near to its placebo in the complexes in all ratios studied. The taste masked complexes can be potentially developed as suitable dosage forms for pediatric use. In summary, complexation of BPM and TA effectively sustained the dissolution and masked the bitter taste of drug for the development of suitable dosage forms for pediatric use.
本研究旨在评估马来酸溴苯那敏(BPM)和鞣酸(TA)的络合潜力,以实现缓释和掩味效果。采用溶剂蒸发法,以甲醇、磷酸盐缓冲液 pH6.8 或 0.1N HCl 为常用溶剂,制备 1:1-1:7(TA 与 BPM 的摩尔比)复合物。采用扫描电子显微镜(SEM)、傅里叶变换红外光谱(FTIR)和固态核磁共振(SSNMR)对复合物进行微观表征,采用差示扫描量热法(DSC)、粉末 X 射线衍射(PXRD)对结晶度进行分析,采用电子舌(e-tongue)对感官评价进行分析,采用 0.1N HCl 和磷酸盐缓冲液 pH6.8 对溶解度进行分析。采用 USP II 法,在 50rpm、500ml 溶出介质(0.1N HCl 或磷酸盐缓冲液 pH6.8)中进行溶出研究。SEM 图像表明,复合物的形态与单个成分完全不同,所有复合物均具有相同的形态特征,与制备时使用的溶剂、pH 或 BPM 和 TA 的比例无关。FTIR 光谱表明 TA 和 BPM 之间存在化学相互作用。DSC、PXRD 和 SSNMR 表明,药物通过形成复合物失去了结晶性。复合物显著降低了 BPM 的溶解度,并在磷酸盐缓冲液 pH6.8 介质中持续释放药物 24 小时。BPM 的苦味完全被掩蔽,这一点可以从欧几里得距离值得到证实,复合物在所有研究比例中距离药物较远,但接近其安慰剂。掩味复合物有望开发为适合儿科使用的合适剂型。总之,BPM 和 TA 的络合作用有效地控制了药物的溶解速度,掩盖了药物的苦味,为开发适合儿科使用的合适剂型提供了可能。